{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prophylaxis+for+Herpes+Simplex",
    "query": {
      "condition": "Prophylaxis for Herpes Simplex"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prophylaxis+for+Herpes+Simplex&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T09:51:05.092Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01225341",
      "title": "Botulinum Toxin A for Herpes Labialis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes Labialis"
      ],
      "interventions": [
        {
          "name": "onabotulinumtoxinA",
          "type": "DRUG"
        },
        {
          "name": "Bacteriostatic normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "DeNova Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-08",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225341"
    },
    {
      "nct_id": "NCT05304351",
      "title": "Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Zoster",
        "Shingles"
      ],
      "interventions": [
        {
          "name": "Amezosvatein Antigen High Dose Arm A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amezosvatein Antigen Low Dose Arm B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amezosvatein Adjuvant Dose Arm D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amezosvatein Adjuvant Dose Arm F",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amezosvatein Adjuvant Dose Arm H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amezosvatein Adjuvant Dose Arm J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amezosvatein Adjuvant Dose Arm L",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Curevo Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1516,
      "start_date": "2022-02-02",
      "completion_date": "2032-03-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 14,
      "location_summary": "Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Oak Brook",
          "state": "Illinois"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05304351"
    },
    {
      "nct_id": "NCT03626376",
      "title": "Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Simplex Virus Keratitis"
      ],
      "interventions": [
        {
          "name": "oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily",
          "type": "DRUG"
        },
        {
          "name": "oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-10",
      "completion_date": "2022-03-02",
      "has_results": false,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626376"
    },
    {
      "nct_id": "NCT00007501",
      "title": "Shingles Prevention Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Zoster",
        "Postherpetic Neuralgia"
      ],
      "interventions": [
        {
          "name": "Varicella-zoster vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 38456,
      "start_date": "1998-11",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2013-07-04",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00007501"
    },
    {
      "nct_id": "NCT05432583",
      "title": "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "BNT163",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 318,
      "start_date": "2022-12-08",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 6,
      "location_summary": "Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432583"
    },
    {
      "nct_id": "NCT04693637",
      "title": "Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Adenovirus Infection",
        "BK Virus Infection",
        "Cytomegalovirus Infections",
        "Epstein-Barr Virus Infections",
        "Human Herpes Virus-6 Infection",
        "JC Virus Infection"
      ],
      "interventions": [
        {
          "name": "Posoleucel (ALVR105)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AlloVir",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-01-15",
      "completion_date": "2023-01-19",
      "has_results": true,
      "last_update_posted_date": "2024-05-09",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Northwest Rectangle",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04693637"
    },
    {
      "nct_id": "NCT02412917",
      "title": "A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Shingles",
        "Herpes Zoster",
        "Postherpetic Neuralgia"
      ],
      "interventions": [
        {
          "name": "FV-100",
          "type": "DRUG"
        },
        {
          "name": "valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ContraVir Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2015-06",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 1,
      "location_summary": "Webster, Texas",
      "locations": [
        {
          "city": "Webster",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02412917"
    },
    {
      "nct_id": "NCT00698568",
      "title": "Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prophylaxis for Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "Herpes simplex candidate vaccine- adjuvanted GSK 208141",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7460,
      "start_date": "1996-10",
      "completion_date": "1999-04",
      "has_results": false,
      "last_update_posted_date": "2008-06-17",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 36,
      "location_summary": "La Jolla, California • Middle Valley, California • San Diego, California + 31 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Middle Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "East Lyme",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698568"
    },
    {
      "nct_id": "NCT00057330",
      "title": "HerpeVac Trial for Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex Infection"
      ],
      "interventions": [
        {
          "name": "HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 8323,
      "start_date": "2003-01-14",
      "completion_date": "2009-08-22",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057330"
    },
    {
      "nct_id": "NCT00855309",
      "title": "Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "acyclovir sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 112,
      "start_date": "2008-11",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-06-26T09:51:05.092Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855309"
    }
  ]
}